BMS CA224-104 Phase 2 Randomized Double-blind Study of Relatlimab plus Nivolumab in Combination with Chemothera-py vs. Nivolumab in Combination with Chemotherapy as First Line Treatment for Participants with Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)
Ongoing - recruitment active · 2021 until 2025
Immunotherapy plays substantial role in first line treatment of NSCLC Stage IV. Current standard of care is – depending on PD-L1 expression- anti-PD-(L)1 alone or in combination with PDCT which has demonstrated significant improvements in OS as well as PFS over chemotherapy. The rationale for combining a LAG-3 inhibitor and and anti-PD-1/PD-L1 agent is based on evidence that LAG-3 has a potential role in T reg suppression and anti-PD-1 resistance and the combination could further improve outcomes.